Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nifekalant versus amiodarone for new-onset atrial fibrillation in acute coronary syndrome
ChiCTR1900021156Phase 4Not yet recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of nifekalant and amiodarone in Atrial fibrillation (AFib) (2 arms), sponsored by Beijing Chaoyang Hospital. Primary endpoint: ECG parameters. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
nifekalantamiodarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR1900021156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021156.